|
EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Mergers & Acquisitions Today, Profdoc AS, a 100% subsidiary of CompuGroup Medical SE & Co. KGaA, has entered into an agreement with the shareholders of Pridok AS to acquire 100% of the shares in Pridok AS. Pridok AS with its corporate seat in Tønsberg, Norway, offers a web-based digital patient journal system for the healthcare sector. In the financial year 2023, it generated revenues of approximately NOK 46.8 million (equals approximately EUR 4.1 million), which corresponds to a year-on-year growth rate of 32%. The consideration for the shares in Pridok AS amount to NOK 404.9 million (equals approximately EUR 35.7 million). Depending on Pridok AS’ development of the business in the financial years 2024 until 2028, additional consideration tranches may become payable up to an aggregate amount of NOK 185 million (approximately EUR 16.3 million). Closing of the transaction is expected on June 25, 2024 and is not subject to material conditions. End of Inside Information
25-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1932989 |
| End of Announcement | EQS News Service |
|
|
1932989 25-Jun-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
